Stemprinter demonstrates prognostic utility in transatac cohort

New york, march 01, 2022 (globe newswire) -- tiziana life sciences ltd.'s (nasdaq: tlsa) former subsidiary, accustem sciences, inc. (otc pink: acmsy) (formerly accustem sciences ltd.), today announced publication of new data in the european journal of cancer. results demonstrate that stemprinter is highly prognostic for risk of distant recurrence in women with breast cancer.
TLSA Ratings Summary
TLSA Quant Ranking